Publications by authors named "I Bardoulat"
Article Synopsis
- ABP 501 is an adalimumab biosimilar approved for immune-mediated inflammatory diseases like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and a study was conducted to analyze its treatment patterns in Germany and France.
- The study included patients who started ABP 501 between October 2018 and March 2020, tracking their persistence and switching behavior based on prior experience with adalimumab products over a year.
- Results showed varying persistence rates among different diseases and countries, with experienced patients often switching back to the original adalimumab, indicating a potential nocebo effect, and highlighting the need for further research.
Therap Adv Gastroenterol
January 2024
Article Synopsis
- - The study evaluated real-world usage of the adalimumab biosimilar ABP 501 for treating inflammatory bowel disease (IBD) by analyzing pharmacy claims data from Germany and France.
- - It included 3362 German and 733 French patients, finding that 54.4% in Germany and 65.3% in France were new to ADA products; median treatment persistence varied between groups, with ADA-naïve patients showing slightly shorter persistence times.
- - Around 53.7% of German patients and 51.0% of French patients adhered to ABP 501 during the first year, while approximately 20% switched to other therapies, often to the original adalimumab reference product
